Skip to content

A clinical trial on Sivathai chooranam in the management of Vatha gunmam (Peptic ulcer disease)

A PROSPECTIVE OPEN LABELLED, SINGLE ARM, NON-RANDOMISED,SINGLE CENTRIC PHASE II CLINICAL EVALUATION OF SIVATHAI CHOORANAM IN THE MANAGEMENT OF VATHA GUNMAM (PEPTIC ULCER DISEASE)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/05/052505
Enrollment
40
Registered
2023-05-11
Start date
Unknown
Completion date
Unknown
Last updated
2023-05-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K273- Acute peptic ulcer, site unspecified, without hemorrhage or perforation

Interventions

Intervention1: Sivathai chooranam: Dosage:500mg-1gm Route:Orally Frequency:twice a day Adjuvant:Hot water Duration: 45 days Control Intervention1: Nil: Nil

Sponsors

Government Siddha Medical College And Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients having symptoms with abdominal pain,fatigue and weakness,bodypain,headache,dizziness,polydipsia,xerostomia,constipation,vomiting and indigestion. 2.Patients who are willing to take upper gastrointestinal endoscopy 3. Patients who are willing to give blood specimen for lab investigation when required. 4.Patient willing to sign the informed consent indicating that they understand the purpose and procedures required for the study and are willing to participating the study

Exclusion criteria

Exclusion criteria: 1.Pregnancy 2.Lactating mother 3. Recent malignancy or radiation therapy 4.Gastro esophageal reflux disease 5.Pancreatitis 6.Inflammotary Bowel Disease 7.Acute hepatitis 8.Patients considered unreliable by the investigator (e.g: drug addiction, Alcohol abuse)

Design outcomes

Primary

MeasureTime frame
The outcome is the reduction in clinical symptoms of abdominal pain, fatigue and weakness, body pain,headache,dizziness ,polydipsia,xerostomia, constipation, vomiting and indigestionTimepoint: 45 days

Secondary

MeasureTime frame
The secondary outcome will be the evaluation of siddha diagnostic parameters assessment of safety profile of trial drug assesment of pharmacological and biochemical parameters of the trial drugTimepoint: 45 days

Countries

India

Contacts

Public ContactProf Dr A Manoharan MDsPhD

Government Siddha Medical College And Hospital

Komalaarumugam1@gmail.com9788122691

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026